• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Bonstein Sara

    6/12/25 4:36:54 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XLO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Bonstein Sara

    (Last) (First) (Middle)
    828 WINTER STREET
    SUITE 300

    (Street)
    WALTHAM MA 02451

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Xilio Therapeutics, Inc. [ XLO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/11/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $0.693 06/11/2025 A 31,000 (1) 06/10/2035 Common Stock 31,000 $0 31,000 D
    Explanation of Responses:
    1. The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
    Remarks:
    Exhibit 24 - Power of Attorney
    /s/ Kevin Brennan, Attorney-in-Fact 06/12/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $XLO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XLO

    DatePrice TargetRatingAnalyst
    12/21/2022$7.00Buy
    Chardan Capital Markets
    1/10/2022$36.00Buy
    HC Wainwright & Co.
    11/16/2021$40.00Buy
    Guggenheim
    11/16/2021$31.00Outperform
    Raymond James
    11/16/2021Outperform
    Cowen & Co.
    11/16/2021$32.00Overweight
    Morgan Stanley
    More analyst ratings

    $XLO
    SEC Filings

    See more
    • Xilio Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)

      6/12/25 4:30:19 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xilio Therapeutics Inc. filed SEC Form 8-K: Leadership Update

      8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)

      6/10/25 4:35:46 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Xilio Therapeutics Inc.

      DEFA14A - Xilio Therapeutics, Inc. (0001840233) (Filer)

      6/3/25 7:43:05 AM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XLO
    Financials

    Live finance-specific insights

    See more
    • Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

      Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended anticipated cash runway into the first quarter of 2026 Company to host investor conference call and webcast today at 8:30 am ET WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane antigen (PSMA), claudi

      2/12/25 7:35:00 AM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

      Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging X

      2/12/25 7:33:00 AM ET
      $ABBV
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

      Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am ESTNORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio's p

      2/12/25 7:30:00 AM ET
      $ABBV
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Ross Robert W.

      4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

      6/12/25 4:37:36 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Brennan Aoife

      4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

      6/12/25 4:37:15 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bonstein Sara

      4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

      6/12/25 4:36:54 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $XLO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $XLO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Chardan Capital Markets initiated coverage on Xilio Therapeutics with a new price target

      Chardan Capital Markets initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $7.00

      12/21/22 7:57:28 AM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Xilio Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $36.00

      1/10/22 6:12:33 AM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Xilio Therapeutics with a new price target

      Guggenheim initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $40.00

      11/16/21 9:07:16 AM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

      WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde (Tunde) Bello, Ph.D., to the company's board of directors. "Tunde is an accomplished leader with a strong track record of successfully developing novel therapies across a broad range of therapeutic areas, including several important cancer immunotherapies for anti-CTLA-4, PD-1 and T-cell engager through all stages of development, and I am thrilled to welcome him to the board," said Paul Clancy, chair of the board of dire

      6/10/25 4:30:00 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

      Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are exercised for cash Xilio may elect to cancel unexercised Series B or Series C warrants proportionately to the amount of non-dilutive capital received, under certain circumstances Financing co-led by new investors Coastlands Capital and Frazier Life Sciences and included participation from Gilead Sciences, Inc., Logos Capital, Samsara BioCapital and other new and existing investors WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology thera

      6/5/25 6:38:24 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective June 1, 2025, the company granted non-qualified stock options to purchase 181,300 shares of its common stock to five new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $1.07 per share, which is equal to the closing price of the company's common stock on May 30, 2025. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock o

      6/3/25 4:30:00 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

      SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

      11/14/24 5:44:28 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

      SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

      11/14/24 4:30:23 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

      SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

      11/12/24 4:50:36 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XLO
    Leadership Updates

    Live Leadership Updates

    See more
    • Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

      WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde (Tunde) Bello, Ph.D., to the company's board of directors. "Tunde is an accomplished leader with a strong track record of successfully developing novel therapies across a broad range of therapeutic areas, including several important cancer immunotherapies for anti-CTLA-4, PD-1 and T-cell engager through all stages of development, and I am thrilled to welcome him to the board," said Paul Clancy, chair of the board of dire

      6/10/25 4:30:00 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

      Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of 2025 Advancing masked T cell engager programs in novel ATACR and SEECR formats for PSMA, CLDN18.2 and STEAP1 Announced collaboration with AbbVie in the first quarter of 2025 to develop novel tumor-activated, antibody-based immunotherapies, including masked T cell engagers WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipe

      3/11/25 7:30:58 AM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

      WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Caroline (Holda) Hensley as chief legal officer. "Caroline is an accomplished lawyer and biotechnology executive who brings a wealth of experience advising public life science companies across all stages of development and commercialization," said René Russo, Pharm.D., president and chief executive officer of Xilio. "Her expertise and strategic insights make her a tremendous addition to our executive team, and we are excited to ha

      12/16/24 7:30:00 AM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XLO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Gilead Sciences, Inc. bought $1,830,377 worth of shares (1,759,978 units at $1.04), increasing direct ownership by 24% to 9,105,451 units (SEC Form 4)

      4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

      12/19/24 4:19:34 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gilead Sciences, Inc. bought $368,790 worth of shares (485,250 units at $0.76), increasing direct ownership by 7% to 7,345,473 units (SEC Form 4)

      4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

      4/3/24 6:50:01 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care